Short answer
IRONWOOD PHARMACEUTICALS INC (IRWD) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $113M (up 32.6% year over year) with net income of $51M.
Q2 2026 key financials · XBRL
- Revenue
- $113M
- +32.6% YoY · +6.1% QoQ
- Net income
- $51M
- +117.3% YoY · +25.8% QoQ
- Operating margin
- 70.2%
- EPS (diluted)
- $0.31
- +121.4% YoY · +29.2% QoQ
Source: XBRL data from the IRONWOOD PHARMACEUTICALS INC (IRWD) Q2 2026 10-Q on SEC EDGAR. USD.
IRONWOOD PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $113.0M, up $27.8M YoY, driven by $24.4M higher U.S. LINZESS net profits
- Operating margin 70.2% vs 53.2% YoY, with operating income $79.3M vs $45.3M
- LINZESS best-performing product, generating $24.4M incremental U.S. net profits
- Apraglutide R&D increased to $18.8M from $17.0M YoY; IW-3300 R&D included a $(0.1)M credit
- STARS-2 initiated in June 2026; management cites regulatory uncertainty and continued substantial R&D investment as headwinds
Risk Factors
- New legal risk: Alkem Paragraph IV certification received June 12, 2026, challenging LINZESS patents
- Most material update: July 2026 New Jersey lawsuit triggered FDA approval stay through December 12, 2028
- Regulatory risk: USPTO IPR or PGR proceedings could invalidate or narrow LINZESS patent protection
- Operational risk: At-risk generic launch could significantly reduce LINZESS revenue within a short period
- Financial risk: LINZESS revenue concentration exposed to rapid erosion following patent-protection loss
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IRONWOOD PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.